AMENDMENT

Subject matter to be added is in bold and underlined.

Subject matter to be deleted is in bold and strikethrough.

In the Claims:

Please amend claims 1-4 as follows.

Please cancel claims 11-15 without prejudice or waiver.

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (Currently amended) A compound of Formula (I):



(I)

or a stereoisomer or a pharmaceutically acceptable salt or hydrate thereof, wherein:

L_1 is a bond;

L_2 is a bond, $-CH_2-$, or $-O-$;

A is phenyl substituted with 0-3 R^{11} and 0-1 R^{12};

B is phenyl substituted with 0-3 R^{11} and 0-1 R^{12};

X^1, X^2, X^3 and X^4 independently represent CR^1, CR^2, or CR^3;

R^1 is H, $-NH_2$, $-NH(C_1\text{-}C_3$ alkyl), $-N(C_1\text{-}C_3$ alkyl)$_2$, $-C(=NH)NH_2$, $-NHC(=NH)NH_2$, $-C(O)NH_2$, $-CH_2NH_2$, $-CH_2NH(C_1\text{-}C_3$ alkyl), $-CH_2N(C_1\text{-}C_3$ alkyl)$_2$, $-CH_2CH_2NH_2$, $-CH_2CH_2NH(C_1\text{-}C_3$ alkyl), $-CH_2CH_2N(C_1\text{-}C_3$ alkyl)$_2$, $-C(=NR^8)NR^7R^9$, $-NHC(=NR^8)NR^7R^9$, $-ONHC(=NR^8)NR^7R^9$, $-NR^8CH(=NR^7)$, $-C(=NR^{8a})NR^7R^9$, $-NHC(=NR^{8a})NR^7R^9$, $-NR^7R^8$, $-C(O)NR^{7a}R^8$, $-S(O)_pNR^8R^9$, F, Cl, Br, I, OCF_3, CF_3, OR^a, SR^a, CN or

C_{1-6} alkyl substituted with 1 R^{1a};

R^{1a} is -C(=NR^8)NR^7R^9, -NHC(=NR^8)NR^7R^9, -ONHC(=NR^8)NR^7R^9, -NR^8CH(=NR^7), -NR^7R^8, -C(O)$NR^{7a}R^8$, -$S(O)_pNR^8R^9$, F, OCF_3, CF_3, OR^a, SR^a, or CN;

R^2 is H, F, Cl, Br, I, OCF_3, CF_3, OR^a, SR^a, CN, NO_2, -NR^7R^8, -C(O)$NR^{7a}R^8$, -NR^{10}C(O)R^b, -$S(O)_pNR^8R^9$, -S(O)R^c, -$S(O)_2R^c$, C_{1-6} alkyl substituted with 0-2 R^{2a}, C_{2-6} alkenyl substituted with 0-2 R^{2a}, C_{2-6} alkynyl substituted with 0-2 R^{2a}, or -$(CH_2)_r$-C_{3-10} carbocycle substituted with 0-3 R^{2b};

each R^{2a} is, independently at each occurrence, H, F, OCF_3, CF_3, OR^a, SR^a, CN, -NR^7R^8, -C(O)$NR^{7a}R^8$, -NR^{10}C(O)R^b, -$S(O)_pNR^8R^9$, -S(O)R^c, or -$S(O)_2R^c$;

each R^{2b} is, independently at each occurrence, H, F, Cl, Br, I, OR^a, SR^a, CN, NO_2, CF_3, -SO_2R^c, -NR^7R^8, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} cycloalkyl, C_{1-4} haloalkyl, C_{1-4} haloalkyloxy-, C_{1-4} alkyloxy-, C_{1-4} alkylthio-, C_{1-4} alkyl-C(O)-, or C_{1-4} alkyl-C(O)NH-;

R^3 is H, F, Cl, Br, I, OCF_3, CF_3, OR^a, SR^a, CN, NO_2, -NR^7R^8, -C(O)$NR^{7a}R^8$, -NR^{10}C(O)R^b, -$S(O)_pNR^8R^9$, -S(O)R^c, -$S(O)_2R^c$, C_{1-6} alkyl substituted with 0-2 R^{3a}, C_{2-6} alkenyl substituted with 0-2 R^{3a}, C_{2-6} alkynyl substituted with 0-2 R^{3a}, or -$(CH_2)_r$-C_{3-10} carbocycle substituted with 0-3 R^{3b};

each R^{3a} is, independently at each occurrence, H, F, OCF_3, CF_3, OR^a, SR^a, CN, -NR^7R^8, -C(O)$NR^{7a}R^8$, -NR^{10}C(O)R^b, -$S(O)_pNR^8R^9$, -S(O)R^c, or -$S(O)_2R^c$;

each R^{3b} is, independently at each occurrence, H, F, Cl, Br, I, OR^a, SR^a, CN, NO_2, CF_3, -SO_2R^c, -NR^7R^8, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} cycloalkyl, C_{1-4} haloalkyl, C_{1-4} haloalkyloxy-, C_{1-4} alkyloxy-, C_{1-4} alkylthio-, C_{1-4} alkyl-C(O)-, or C_{1-4} alkyl-C(O)NH-;

R^4 is phenyl substituted with 0-3 R^{4b};

each R^{4b} is, independently at each occurrence, H, OH, Cl, F, Br, I, CN, NO_2, CF_3, -C(O)OR^a, -SO_2R^c, -NR^7R^8, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} cycloalkyl,

C_{1-4} haloalkyl, C_{1-4} haloalkyloxy-, C_{1-4} alkyloxy-, C_{1-4} alkylthio-, C_{1-4} alkyl-C(O)-, C_{1-4} alkyl-C(O)NH-, $-C(O)NR^{7a}R^8$, $-NR^{10}C(O)R^b$, $-NR^{10}S(O)_2NR^8R^9$, or $-S(O)_2NR^8R^9$;

R^5 is H, C_{1-4} haloalkyl, or C_{1-6} alkyl substituted with 0-3 R^{5a};

each R^{5a} is, independently at each occurrence, H, C_{1-4} alkyl, OR^a, F, =O, CF_3, CN, $-C(O)R^a$, $-C(O)OR^a$, $-C(O)NR^{7a}R^8$, or $-S(O)_pR^c$;

each R^6 is, independently at each occurrence, H, C_{1-4} alkyl, $-(CH_2)_rC(O)OR^a$, $-(CH_2)_rS(O)_2NR^{7a}R^8$, or $-(CH_2)_rOR^a$;

each R^{6a} is, independently at each occurrence, H or C_{1-4} alkyl;

each R^7 is, independently at each occurrence, H, C_{1-6} alkyl, $-(CH_2)_n$-phenyl, (C_{1-6} alkyl)C(O)-, (C_{6-10} aryl)-C_{0-4} alkyl-C(O)-, (C_{3-6} cycloalkyl)-C_{0-4} alkyl-C(O)-, (C_{1-4} alkyl)OC(O)-, (C_{6-10} aryl)-C_{0-4} alkyl-OC(O)-, (C_{1-4} alkyl)-C(O)O-(C_{1-4} alkyl)-OC(O)-, (C_{6-10} aryl)-C(O)O-(C_{1-4} alkyl)-OC(O)-, (C_{1-6} alkyl)-NHC(O)-, (C_{6-10} aryl)-C_{0-4} alkyl-NHC(O)-, (C_{1-6} alkyl)-$S(O)_2$-, (C_{6-10} aryl)-(C_{0-4} alkyl)-$S(O)_2$-, (C_{1-6} alkyl)$_2$NC(O)-, phenyl-NHC(O)-, benzyl-NHC(O)-, (phenyl)(C_{1-6} alkyl)NC(O)-, or (benzyl)(C_{1-6} alkyl)NC(O)-, wherein said phenyl and aryl are substituted with 0-2 R^f;

each R^{7a} is, independently at each occurrence, H, C_{1-4} alkyl substituted with 0-2 R^{7b} or 0-2 R^{7c}, or $-(CH_2)_r$-C_{3-10} carbocycle substituted with 0-3 R^f;

each R^{7b} is, independently at each occurrence, =O, OR^g, F, Cl, Br, I, CN, NO_2, $-NR^7R^8$, $-C(O)R^g$, $-C(O)OR^g$, $-NR^8C(O)R^g$, $-C(O)NR^8R^9$, $-NR^8C(O)NR^8R^9$, $-SO_2NR^8R^9$, $-NR^8SO_2NR^8R^9$, $-NR^8SO_2$-C_{1-4} alkyl, $-NR^8SO_2CF_3$, $-NR^8SO_2$-phenyl, $-S(O)_2CF_3$, $-S(O)_p$-C_{1-4} alkyl, $-S(O)_p$-phenyl, or $-(CF_2)_rCF_3$;

each R^{7c} is, independently at each occurrence, C_{3-10} carbocycle substituted with 0-3 R^f;

each R^8 is, independently at each occurrence, H, C_{1-6} alkyl, or $-(CH_2)_n$-phenyl;

each R^{8a} is, independently at each occurrence, H, OH, C_{1-6} alkyl, $-(CH_2)_n$-phenyl, (C_{1-6} alkyl)C(O)-, (C_{6-10} aryl)-C_{0-4} alkyl-C(O)-,

(C_{3-6} cycloalkyl)-C_{0-4} alkyl-C(O)-, (C_{1-4} alkyl)OC(O)-, (C_{6-10} aryl)-C_{0-4} alkyl-OC(O)-, (C_{1-4} alkyl)-C(O)O-(C_{1-4} alkyl)-OC(O)-, (C_{6-10} aryl)-C(O)O-(C_{1-4} alkyl)-OC(O)-, (C_{1-6} alkyl)-NHC(O)-, (C_{6-10} aryl)-C_{0-4} alkyl-NHC(O)-, (C_{1-6} alkyl)-$S(O)_2$-, (C_{6-10} aryl)-(C_{0-4} alkyl)-$S(O)_2$-, C_{1-4} alkoxy, (C_{1-4} alkyl)C(O)O-, or (C_{6-10} aryl)-(C_{0-4} alkyl)-C(O)O-; wherein said phenyl and aryl are substituted with 0-2 R^f;

each R^9 is, independently at each occurrence, H, C_{1-6} alkyl, or -$(CH_2)_n$-phenyl;

each R^{10} is, independently at each occurrence, H, C_{1-6} alkyl substituted with 0-2 R^{10a}, C_{2-6} alkenyl substituted with 0-2 R^{10a}, C_{2-6} alkynyl substituted with 0-2 R^{10a}, (C_{1-6} alkyl)C(O)-, (C_{3-6} cycloalkyl)C_{1-3} alkyl-C(O)-, (C_{3-6} cycloalkyl)C(O)-, phenyl-C(O)-, benzyl-C(O)-, benzyl-$S(O)_2$-, (C_{1-6} alkyl)NHC(O)-, (C_{1-6} alkyl)$_2$NC(O)-, phenyl-NHC(O)-, benzyl-NHC(O)-, (phenyl)(C_{1-6} alkyl)NC(O)-, (benzyl)(C_{1-6} alkyl)NC(O)-, (C_{1-6} alkyl)-$S(O)_2$-, phenyl-$S(O)_2$-, or -$(CH_2)_r$-C_{3-10} carbocycle substituted with 0-3 R^d;

each R^{10a} is, independently at each occurrence, H, C_{1-4} alkyl, OR^a, Cl, F, Br, I, =O, CF_3, CN, NO_2, -$C(O)R^a$, -$C(O)OR^a$, -$C(O)NR^{7a}R^8$, or -$S(O)_pR^c$;

each R^{11} is, independently at each occurrence, H, =O, -$(CH_2)_r$-OR^a, F, Cl, Br, I, CN, NO_2, -$(CH_2)_r$-NR^7R^8, -$C(O)R^a$, -$C(O)OR^a$, -$NR^8C(O)R^a$, -$NR^8C(O)OR^a$, -$C(O)NR^{7a}R^8$, -$NR^8C(O)NR^8R^9$, -$SO_2NR^8R^9$, -$NR^8SO_2NR^8R^9$, -NR^8SO_2-C_{1-4} alkyl, -$NR^8SO_2CF_3$, -NR^8SO_2-phenyl, -$S(O)_2CF_3$, -$S(O)_p$-C_{1-4} alkyl, -$S(O)_p$-phenyl, -$(CF_2)_rCF_3$, C_{1-6} alkyl substituted with 0-2 R^{11a}, C_{2-6} alkenyl substituted with 0-2 R^{11a}, C_{2-6} alkynyl substituted with 0-2 R^{11a}, C_{1-6} alkyl substituted with 0-2 R^{11b}, C_{2-6} alkenyl substituted with 0-2 R^{11b}, or C_{2-6} alkynyl substituted with 0-2 R^{11b};

each R^{11a} is, independently at each occurrence, =O, OR^a, F, Cl, Br, I, CN, NO_2, -NR^7R^8, -$C(O)R^a$, -$C(O)OR^a$, -$NR^8C(O)R^a$, -$C(O)NR^{7a}R^8$, -$NR^8C(O)NR^8R^9$, -$SO_2NR^8R^9$, -$NR^8SO_2NR^8R^9$, -NR^8SO_2-C_{1-4} alkyl, -$NR^8SO_2CF_3$, -NR^8SO_2-phenyl, -$S(O)_2CF_3$, -$S(O)_p$-C_{1-4} alkyl, -$S(O)_p$-phenyl, or -$(CF_2)_rCF_3$;

each R^{11b} is, independently at each occurrence, C_{3-10} carbocycle substituted with 0-3 R^d; ~~or a 5-12 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$, and substituted 0-3 R^d;~~

each R^{12} is, independently at each occurrence, OR^{12a}, $-C(O)NR^{7a}R^8$, $-(CH_2)_rCO_2R^{12a}$, $-(CH_2)_rSO_3H$, $-OSO_3H$, $-(CH_2)_rPO_3H$, $-OPO_3H_2$, $-PO_3H_2$, $-NHPO_3H_2$, $-NHCOCF_3$, $-NHSO_2CF_3$, $-CONHNHSO_2CF_3$, $-C(CF_3)_2OH$, $-SO_2NHR^{12a}$, $-CONHSO_2NHR^{12a}$, $-SO_2NHCOR^{12a}$, $-SO_2NHCO_2R^{12a}$, $-CONHSO_2R^{12b}$, $-NHSO_2R^{12b}$, $-CONHOR^{12b}$,





or

;

each R^{12a} is, independently at each occurrence, H, C_{1-6} alkyl, or $-(CH_2)_r$-C_{3-10} carbocycle substituted with 0-3 R^d; ~~or $-(CH_2)_r$ 5-10 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$, and substituted with 0-3 R^d;~~

each R^{12b} is, independently at each occurrence, C_{1-6} alkyl substituted with 0-2 R^{12c}, C_{2-6} alkenyl substituted with 0-2 R^{12c}, C_{2-6} alkynyl substituted with R^{12c}, or $-(CH_2)_r$-C_{3-10} carbocycle substituted with 0-3 R^{12c}; ~~or $-(CH_2)_r$ 5-10 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$, and substituted with 0-3 R^{12c};~~

each R^{12c} is, independently at each occurrence, H, F, Cl, Br, I, CF_3, OCF_3, CN, NO_2, OR^a, $-CO_2R^a$, $-NR^7R^8$, $-SO_2R^c$, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, or

-$(CH_2)_r$-C_{3-10} carbocycle substituted with 0-3 R^d; ~~or -$(CH_2)_r$-5-10 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$, and substituted with 0-3 R^d;~~

R^{13} is H, C_{1-4} alkyl, $(NR^7R^8)C_{1-4}$ alkyl, $(SR^c)C_{1-4}$ alkyl, $(OR^a)C_{1-4}$ alkyl, OR^a, F, CF_3, -$C(O)R^a$, -$C(O)OR^a$, -$C(O)NR^{7a}R^8$, or -$S(O)_pR^c$;

R^{14} is H, C_{1-4} alkyl, $(NR^7R^8)C_{1-4}$ alkyl, $(SR^c)C_{1-4}$ alkyl, $(OR^a)C_{1-4}$ alkyl, OR^a, F, CF_3, -$C(O)R^a$, -$C(O)OR^a$, -$C(O)NR^{7a}R^8$, or -$S(O)_pR^c$;

alternately, R^{13} and R^{14} may be taken together to be =O;

R^{15} is H or C_{1-4} alkyl;

R^{16} is H, C_{1-4} alkyl, benzyl, C_{1-4} alkyl-C(O)-, C_{1-4} alkyl-$S(O)_2$-, or C_{1-4} alkyl-OC(O)-;

each R^a is, independently at each occurrence, H, C_{1-4} alkyl, -$(CH_2)_r$-CO_2R^g, -$(CH_2)_r$-C_{3-7} cycloalkyl, or -$(CH_2)_r$-C_{6-10} aryl, wherein said aryl is substituted with 0-2 R^f;

each R^b is, independently at each occurrence, CF_3, OH, C_{1-4} alkoxy, C_{1-6} alkyl, or -$(CH_2)_r$-C_{3-10} carbocycle substituted with 0-2 R^d;

each R^c is, independently at each occurrence, C_{1-4} alkyl, C_{6-10} aryl, or (C_{6-10} aryl)-C_{1-4} alkyl, wherein said aryl is substituted with 0-2 R^d;

each R^d is, independently at each occurrence, H, =O, OR^a, F, Cl, Br, I, CN, NO_2, -NR^7R^8, -$C(O)R^a$, -$C(O)OR^a$, -$NR^8C(O)R^a$, -$C(O)NR^{7a}R^8$, -$SO_2NR^8R^9$, -$NR^8SO_2NR^8R^9$, -NR^8SO_2-C_{1-4} alkyl, -$NR^8SO_2CF_3$, -NR^8SO_2-phenyl, -$S(O)_2CF_3$, -$S(O)_p$-C_{1-4} alkyl, -$S(O)_p$-phenyl, -$(CF_2)_rCF_3$, C_{1-6} alkyl substituted with 0-2 R^e, C_{2-6} alkenyl substituted with 0-2 R^e, or C_{2-6} alkynyl substituted with 0-2 R^e;

each R^e is, independently at each occurrence, =O, OR^a, F, Cl, Br, I, CN, NO_2, -NR^8R^9, -$C(O)R^a$, -$C(O)OR^a$, -$NR^8C(O)R^a$, -$C(O)NR^{7a}R^8$, -$SO_2NR^8R^9$, -$NR^8SO_2NR^8R^9$, -NR^8SO_2-C_{1-4} alkyl, -$NR^8SO_2CF_3$, -NR^8SO_2-phenyl, -$S(O)_2CF_3$, -$S(O)_p$-C_{1-4} alkyl, -$S(O)_p$-phenyl, or -$(CF_2)_rCF_3$;

each R^f is, independently at each occurrence, H, =O, OR^g, F, Cl, Br, I, CN, NO_2, $-NR^8R^9$, $-C(O)R^g$, $-C(O)OR^g$, $-NR^8C(O)R^g$, $-C(O)NR^8R^9$, $-SO_2NR^8R^9$, $-NR^8SO_2NR^8R^9$, $-NR^8SO_2$-C_{1-4} alkyl, $-NR^8SO_2CF_3$, $-NR^8SO_2$-phenyl, $-S(O)_2CF_3$, $-S(O)_p$-C_{1-4} alkyl, $-S(O)_p$-phenyl, $-(CF_2)_rCF_3$, C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl;

each R^g is, independently at each occurrence, H, C_{1-6} alkyl, or $-(CH_2)_n$-phenyl;

n, at each occurrence, is selected from 0, 1, 2, 3, and 4;

p, at each occurrence, is selected from 0, 1, and 2;

r, at each occurrence, is selected from 0, 1, 2, 3, and 4; and

provided that when L_1 is a bond ~~and A is phenyl or a 6 membered aromatic N-heterocycle~~, then ring A is not substituted ortho to L_1 with OH, halogen, $-CO_2H$, $-C(O)O$-C_{1-4} alkyl, -O-phenyl, -O-benzyl, $-NR^7R^8$, $-CH_2OR^a$, haloalkyl, $-S$-C_{1-4} alkyl, or $-NHSO_2$-C_{1-4} alkyl.

2. (Currently amended) A compound according to Claim 1, wherein the compound is of Formula (Ia):



(Ia)

or a stereoisomer or a pharmaceutically acceptable salt or hydrate thereof, wherein:

A is phenyl substituted with 0-2 R^{11} and 0-1 R^{12};

B is phenyl substituted with 0-2 R^{11} and 0-1 R^{12};

R^1 is H, $-NH_2$, $-NH(C_1$-C_3 alkyl), $-N(C_1$-C_3 alkyl)$_2$, $-C(=NH)NH_2$, $-NHC(=NH)NH_2$, $-C(O)NH_2$, $-CH_2NH_2$, $-CH_2NH(C_1$-C_3 alkyl), $-CH_2N(C_1$-C_3 alkyl)$_2$, $-CH_2CH_2NH_2$, $-CH_2CH_2NH(C_1$-C_3 alkyl), $-CH_2CH_2N(C_1$-C_3 alkyl)$_2$, $-C(=NR^8)NR^7R^9$, $-NHC(=NR^8)NR^7R^9$,

-ONHC(=NR^8)NR^7R^9, -NR^8CH(=NR^7), -C(=NR^{8a})NR^7R^9, -NHC(=NR^{8a})NR^7R^9, -NR^7R^8, -C(O)$NR^{7a}R^8$, -$S(O)_pNR^8R^9$, F, Cl, Br, I, OCF_3, CF_3, OR^a, SR^a, CN or C_{1-6} alkyl substituted with 1 R^{1a};

R^{1a} is -C(=NR^8)NR^7R^9, -NHC(=NR^8)NR^7R^9, -ONHC(=NR^8)NR^7R^9, -NR^8CH(=NR^7), -NR^7R^8, -C(O)$NR^{7a}R^8$, -$S(O)_pNR^8R^9$, F, OCF_3, CF_3, OR^a, SR^a, or CN;

R^2 is H, F, OR^a, CN, -NR^7R^8, -C(O)$NR^{7a}R^8$, -NR^{10}C(O)R^b, -$S(O)_pNR^8R^9$, -S(O)R^c, -$S(O)_2R^c$, C_{1-6} alkyl substituted with 0-2 R^{2a}, or -$(CH_2)_r$-C_3-C_7 carbocycle substituted with 0-2 R^{2b};

each R^{2a} is, independently at each occurrence, H, F, OCF_3, CF_3, OR^a, SR^a, CN, -NR^7R^8, -C(O)$NR^{7a}R^8$, -NR^{10}C(O)R^b, -$S(O)_pNR^8R^9$, -S(O)R^c, or -$S(O)_2R^c$;

each R^{2b} is, independently at each occurrence, H, F, OR^a, SR^a, CN, NO_2, CF_3, -SO_2R^c, -NR^7R^8, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, C_1-C_4 haloalkyl, C_1-C_4 haloalkyloxy-, C_1-C_4 alkyloxy-, C_1-C_4 alkylthio-, C_1-C_4 alkyl-C(O)-, or C_1-C_4 alkyl-C(O)NH-;

R^4 is phenyl substituted with 0-3 R^{4b};

each R^{4b} is, independently at each occurrence, H, OH, Cl, F, Cl, Br, CN, NO_2, CF_3, -C(O)OR^a, -SO_2R^c, -NR^7R^8, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, C_1-C_4 haloalkyl, C_1-C_4 haloalkyloxy-, C_1-C_4 alkyloxy-, C_1-C_4 alkylthio-, C_1-C_4 alkyl-C(O)-, C_1-C_4 alkyl-C(O)NH-, -C(O)$NR^{7a}R^8$, -NR^{10}C(O)R^b, -$NR^{10}S(O)_2NR^8R^9$, or -$S(O)_2NR^8R^9$;

R^5 is H, C_1-C_4 haloalkyl, or C_1-C_6 alkyl substituted with 0-2 R^{5a};

each R^6 is, independently at each occurrence, H, C_{1-4} alkyl, -$(CH_2)_r$C(O)OR^a, -$(CH_2)_rS(O)_2NR^{7a}R^8$, or -$(CH_2)_rOR^a$;

each R^{6a} is, independently at each occurrence, H or C_{1-4} alkyl;

each R^7 is, independently at each occurrence, H, C_{1-6} alkyl, -$(CH_2)_n$-phenyl, (C_{1-6} alkyl)C(O)-, (C_{6-10} aryl)-C_{0-4} alkyl-C(O)-, (C_{3-6} cycloalkyl)-C_{0-4} alkyl-C(O)-, (C_{1-4} alkyl)OC(O)-, (C_{6-10} aryl)-C_{0-4} alkyl-OC(O)-,

(C_{1-4} alkyl)-C(O)O-(C_{1-4} alkyl)-OC(O)-, (C_{6-10} aryl)-C(O)O-(C_{1-4} alkyl)-OC(O)-, (C_{1-6} alkyl)-NHC(O)-, (C_{6-10} aryl)-C_{0-4} alkyl-NHC(O)-, (C_{1-6} alkyl)-$S(O)_2$-, (C_{6-10} aryl)-(C_{0-4} alkyl)-$S(O)_2$-, (C_{1-6} alkyl)$_2$NC(O)-, phenyl-NHC(O)-, benzyl-NHC(O)-, (phenyl)(C_{1-6} alkyl)NC(O)-, or (benzyl)(C_{1-6} alkyl)NC(O)-, wherein said phenyl and aryl are substituted with 0-2 R^f;

each R^{7a} is, independently at each occurrence, H, C_{1-4} alkyl substituted with 0-1 R^{7b} or 0-1 R^{7c}, -$(CH_2)_r$-C_{3-7} cycloalkyl substituted with 0-2 R^f, or -$(CH_2)_r$-phenyl substituted with 0-3 R^f;

each R^{7b} is, independently at each occurrence, =O, OR^g, F, Cl, Br, I, CN, NO_2, $-NR^7R^8$, $-C(O)R^g$, $-C(O)OR^g$, $-NR^8C(O)R^g$, $-C(O)NR^8R^9$, $-NR^8C(O)NR^8R^9$, $-SO_2NR^8R^9$, $-NR^8SO_2NR^8R^9$, $-NR^8SO_2$-C_{1-4} alkyl, $-NR^8SO_2CF_3$, $-NR^8SO_2$-phenyl, $-S(O)_2CF_3$, $-S(O)_p$-C_{1-4} alkyl, $-S(O)_p$-phenyl, or $-(CF_2)_rCF_3$;

R^{7c} is C_{3-10} carbocycle substituted with 0-3 R^f;

each R^8 is, independently at each occurrence, H, C_{1-6} alkyl, or -$(CH_2)_n$-phenyl;

each R^{8a} is, independently at each occurrence, H, OH, C_{1-6} alkyl, -$(CH_2)_n$-phenyl, (C_{1-6} alkyl)C(O)-, (C_{6-10} aryl)-C_{0-4} alkyl-C(O)-, (C_{3-6} cycloalkyl)-C_{0-4} alkyl-C(O)-, (C_{1-4} alkyl)OC(O)-, (C_{6-10} aryl)-C_{0-4} alkyl-OC(O)-, (C_{1-4} alkyl)-C(O)O-(C_{1-4} alkyl)-OC(O)-, (C_{6-10} aryl)-C(O)O-(C_{1-4} alkyl)-OC(O)-, (C_{1-6} alkyl)-NHC(O)-, (C_{6-10} aryl)-C_{0-4} alkyl-NHC(O)-, (C_{1-6} alkyl)-$S(O)_2$-, (C_{6-10} aryl)-(C_{0-4} alkyl)-$S(O)_2$-, C_{1-4} alkoxy, (C_{1-4} alkyl)C(O)O-, or (C_{6-10} aryl)-(C_{0-4} alkyl)-C(O)O-; wherein said phenyl and aryl are substituted with 0-2 R^f;

each R^9 is, independently at each occurrence, H, C_{1-6} alkyl, or -$(CH_2)_n$-phenyl;

each R^{10} is, independently at each occurrence, H, C_{1-6} alkyl substituted with 0-2 R^{10a}, C_{2-6} alkenyl substituted with 0-2 R^{10a}, C_{2-6} alkynyl substituted with 0-2 R^{10a}, (C_{1-6} alkyl)C(O)-, (C_{3-6} cycloalkyl)C_{1-3} alkyl-C(O)-, (C_{3-6} cycloalkyl)C(O)-, phenyl-C(O)-, benzyl-C(O)-, benzyl-$S(O)_2$-, (C_{1-6} alkyl)NHC(O)-, (C_{1-6} alkyl)$_2$NC(O)-, phenyl-NHC(O)-, benzyl-NHC(O)-, (phenyl)(C_{1-6} alkyl)NC(O)-,

(benzyl)(C_{1-6} alkyl)NC(O)-, (C_{1-6} alkyl)-S(O)$_2$-, phenyl-S(O)$_2$-, or -$(CH_2)_r$-C_{3-10} carbocycle substituted with 0-3 R^d;

each R^{10a} is, independently at each occurrence, H, C_{1-4} alkyl, OR^a, Cl, F, Cl, Br, I, =O, CF_3, CN, NO_2, -C(O)R^a, -C(O)OR^a, -C(O)$NR^{7a}R^8$, or -S(O)$_p$$R^c$;

each R^{11} is, independently at each occurrence, H, =O, -$(CH_2)_r$-OR^a, F, Cl, Br, I, CN, NO_2, -$(CH_2)_r$-NR^7R^8, -C(O)R^a, -C(O)OR^a, -NR^8C(O)R^a, -NR^8C(O)OR^a, -C(O)$NR^{7a}R^8$, -NR^8C(O)NR^8R^9, -$SO_2NR^8R^9$, -$NR^8SO_2NR^8R^9$, -NR^8SO_2-C_{1-4} alkyl, -$NR^8SO_2CF_3$, -NR^8SO_2-phenyl, -S(O)$_2$$CF_3$, -S(O)$_p$-$C_{1-4}$ alkyl, -S(O)$_p$-phenyl, -$(CF_2)_r$$CF_3$, C_{1-6} alkyl substituted with 0-2 R^{11a}, C_{2-6} alkenyl substituted with 0-2 R^{11a}, C_{2-6} alkynyl substituted with 0-2 R^{11a}, C_{1-6} alkyl substituted with 0-2 R^{11b}, C_{2-6} alkenyl substituted with 0-2 R^{11b}, or C_{2-6} alkynyl substituted with 0-2 R^{11b};

each R^{11a} is, independently at each occurrence, =O, OR^a, F, Cl, Br, I, CN, NO_2, -NR^7R^8, -C(O)R^a, -C(O)OR^a, -NR^8C(O)R^a, -C(O)$NR^{7a}R^8$, -NR^8C(O)NR^8R^9, -$SO_2NR^8R^9$, -$NR^8SO_2NR^8R^9$, -NR^8SO_2-C_{1-4} alkyl, -$NR^8SO_2CF_3$, -NR^8SO_2-phenyl, -S(O)$_2$$CF_3$, -S(O)$_p$-$C_{1-4}$ alkyl, -S(O)$_p$-phenyl, or -$(CF_2)_r$$CF_3$;

each R^{11b} is, independently at each occurrence, C_{3-10} carbocycle substituted with 0-3 R^d; ~~or a 5-12 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)$_p$, and substituted 0-3 R^d;~~

each R^{12} is, independently at each occurrence, OR^{12a}, -C(O)$NR^{7a}R^8$, -$(CH_2)_r$$CO_2R^{12a}$, -$(CH_2)_r$$SO_3H$, -$OSO_3H$, -$(CH_2)_r$$PO_3H$, -$OPO_3H_2$, -$PO_3H_2$, -$NHPO_3H_2$, -$NHCOCF_3$, -$NHSO_2CF_3$, -$CONHNHSO_2CF_3$, -$C(CF_3)_2OH$, -$SO_2NHR^{12a}$, -$CONHSO_2NHR^{12a}$, -$SO_2NHCOR^{12a}$, -$SO_2NHCO_2R^{12a}$, -$CONHSO_2R^{12b}$,

$-NHSO_2R^{12b}$, $-CONHOR^{12b}$,





or

;

each R^{12a} is, independently at each occurrence, H, C_{1-6} alkyl, or $-(CH_2)_r-C_{3-10}$ carbocycle substituted with 0-3 R^d; ~~or $-(CH_2)_r$-5-10 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$, and substituted with 0-3 R^d;~~

each R^{12b} is, independently at each occurrence, C_1-C_6 alkyl substituted with 0-2 R^{12c}, C_2-C_6 alkenyl substituted with 0-2 R^{12c}, C_2-C_6 alkynyl substituted with 0-2 R^{12c}, or $-(CH_2)_r-C_3$-C_{10} carbocycle substituted with 0-3 R^{12c}~~, or $-(CH_2)_r$-5-10 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$, and substituted with 0-3 R^{12c}~~;

each R^{12c} is, independently at each occurrence, H, F, Cl, Br, I, CF_3, OCF_3, CN, NO_2, OR^a, $-CO_2R^a$, $-NR^7R^8$, $-SO_2R^c$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, or $-(CH_2)_r-C_{3-10}$ carbocycle substituted with 0-3 R^d; ~~or $-(CH_2)_r$-5-10 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$, and substituted with 0-3 R^d;~~

R^{13} is H or C_{1-4} alkyl;

R^{14} is H or C_{1-4} alkyl;

R^{16} is H, C_{1-4} alkyl, benzyl, C_{1-4} alkyl-C(O)-, C_{1-4} alkyl-$S(O)_2$-, or C_{1-4} alkyl-OC(O)-;

each R^a is, independently at each occurrence, H, C_{1-4} alkyl, $-(CH_2)_r-CO_2R^g$, $-(CH_2)_r-C_{3-7}$ cycloalkyl, or $-(CH_2)_r-C_{6-10}$ aryl, wherein said aryl is substituted with 0-2 R^f;

each R^b is, independently at each occurrence, CF_3, OH, C_{1-4} alkoxy, C_{1-6} alkyl, or $-(CH_2)_r-C_{3-10}$ carbocycle substituted with 0-2 R^d;

each R^c is, independently at each occurrence, C_{1-4} alkyl, C_{6-10} aryl, or (C_{6-10} aryl)-C_{1-4} alkyl;

each R^d is, independently at each occurrence, H, =O, OR^a, F, Cl, Br, I, CN, NO_2, $-NR^7R^8$, $-C(O)R^a$, $-C(O)OR^a$, $-NR^8C(O)R^a$, $-C(O)NR^{7a}R^8$, $-SO_2NR^8R^9$, $-NR^8SO_2NR^8R^9$, $-NR^8SO_2-C_{1-4}$ alkyl, $-NR^8SO_2CF_3$, $-NR^8SO_2$-phenyl, $-S(O)_2CF_3$, $-S(O)_p-C_{1-4}$ alkyl, $-S(O)_p$-phenyl, $-(CF_2)_rCF_3$, C_1-C_6 alkyl substituted with 0-2 R^e, C_2-C_6 alkenyl substituted with 0-2 R^e, or C_2-C_6 alkynyl substituted with 0-2 R^e;

each R^e is, independently at each occurrence, =O, OR^a, F, Cl, Br, I, CN, NO_2, $-NR^8R^9$, $-C(O)R^a$, $-C(O)OR^a$, $-NR^8C(O)R^a$, $-C(O)NR^{7a}R^8$, $-SO_2NR^8R^9$, $-NR^8SO_2NR^8R^9$, $-NR^8SO_2-C_{1-4}$ alkyl, $-NR^8SO_2CF_3$, $-NR^8SO_2$-phenyl, $-S(O)_2CF_3$, $-S(O)_p-C_{1-4}$ alkyl, $-S(O)_p$-phenyl, or $-(CF_2)_rCF_3$;

each R^f is, independently at each occurrence, H, =O, OR^g, F, Cl. Br, I, CN, NO_2, $-NR^8R^9$, $-C(O)R^g$, $-C(O)OR^g$, $-NR^8C(O)R^g$, $-C(O)NR^8R^9$, $-SO_2NR^8R^9$, $-NR^8SO_2NR^8R^9$, $-NR^8SO_2-C_{1-4}$ alkyl, $-NR^8SO_2CF_3$, $-NR^8SO_2$-phenyl, $-S(O)_2CF_3$, $-S(O)_p-C_{1-4}$ alkyl, $-S(O)_p$-phenyl, $-(CF_2)_rCF_3$, C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl;

each R^g is, independently at each occurrence, H, C_{1-6} alkyl, or $-(CH_2)_n$-phenyl;

n, at each occurrence, is selected from 0, 1, 2, 3, and 4;

p, at each occurrence, is selected from 0, 1, and 2; and

r, at each occurrence, is selected from 0, 1, 2, 3, and 4;

provided that ~~A is phenyl or a 6-membered aromatic N-heterocycle, then~~ ring A is not substituted ortho to the tetrahydroquinoline with OH, halogen, $-CO_2H$, $-C(O)O-C_{1-4}$ alkyl, -O-phenyl, -O-benzyl, $-NR^7R^8$, $-CH_2OR^a$, haloalkyl, $-S-C_{1-4}$ alkyl, or $-NHSO_2-C_{1-4}$ alkyl.

3. (Currently amended) A compound according to Claim 2, wherein the compound is of Formula (Ib):



(Ib)

or a stereoisomer or a pharmaceutically acceptable salt or hydrate thereof, wherein:

B is phenyl substituted with 0-2 R^{11} and 0-1 R^{12};

R^1 is H, F, Cl, -C(=NH)NH_2, -CH_2NH_2, -C(O)$NR^{7a}R^8$, OMe, or CN;

R^4 is H, -$(CH_2)_r$-C_3-C_7 cylcoalkyl substituted with 0-2 R^{4b}, or -$(CH_2)_r$-phenyl substituted with 0-3 R^{4b};

each R^{4b} is, independently at each occurrence, H, OH, Cl, F, Cl, Br, CN, NO_2, CF_3, -C(O)OR^a, -SO_2R^c, -NR^7R^8, C_1-C_4 alkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl, C_3-C_6 cycloalkyl, C_1-C_4 haloalkyl, C_1-C_4 haloalkyloxy-, C_1-C_4 alkyloxy-, C_1-C_4 alkylthio-, C_1-C_4 alkyl-C(O)-, or C_1-C_4 alkyl-C(O)NH-;

R^5 is H, C_1-C_3 alkyl, or C_3-C_6 cycloalkyl;

each R^7 is, independently at each occurrence, H, C_{1-6} alkyl, or benzyl;

each R^{7a} is, independently at each occurrence, H, C_{1-4} alkyl substituted with 0-1 R^{7b} or 0-1 R^{7c}, -$(CH_2)_r$-C_{3-7} cycloalkyl substituted with 0-1 R^f, or -$(CH_2)_r$-phenyl substituted with 0-2 R^f;

each R^{7b} is, independently at each occurrence, OR^g, F, CN, -NR^7R^8, -C(O)R^g, -C(O)OR^g, -NR^8C(O)R^g, -C(O)NR^8R^9, -$SO_2NR^8R^9$, or -NR^8SO_2-C_{1-4} alkyl;

R^{7c} is C_{3-7} cycloalkyl substituted with 0-1 R^f, or phenyl substituted with 0-2 R^f;

each R^8 is, independently at each occurrence, H, C_{1-6} alkyl, or benzyl;

each R^9 is, independently at each occurrence, H, C_{1-6} alkyl, or benzyl;

each R^{11} is, independently at each occurrence, H, F, -$(CH_2)_r$-OR^a, CN, -$(CH_2)_r$-NR^7R^8, -C(O)OR^a, -NR^8C(O)R^a, -NR^8C(O)OR^a, -C(O)$NR^{7a}R^8$,

$-NR^8C(O)NR^8R^9$, $-SO_2NR^8R^9$, or $-NR^8SO_2-C_{1-4}$ alkyl;

R^{12} is $-C(O)NR^{7a}R^8$, $-(CH_2)_rCO_2R^{12a}$, $-SO_2NHR^{12a}$, $-CONHSO_2NHR^{12a}$, $-SO_2NHCOR^{12a}$, $-SO_2NHCO_2R^{12a}$, $-CONHSO_2R^{12b}$, $-NHSO_2R^{12b}$, $-CONHSO_2R^{12b}$, $-CONHOR^{12b}$, or $-(CH_2)_r$-5-tetrazolyl-;

each R^{12a} is, independently at each occurrence, H or C_{1-6} alkyl;

each R^{12b} is, independently at each occurrence, C_1-C_4 alkyl substituted with 0-1 R^{12c}, C_2-C_4 alkenyl substituted with 0-1 R^{12c}, C_2-C_4 alkynyl substituted with 0-1 R^{12c}, or $-(CH_2)_r$-C_3-C_7 carbocycle substituted with 0-2 R^{12c}~~, or $-(CH_2)_r$-5-6 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$, and substituted with 0-2 R^{12c}~~;

each R^{12c} is, independently at each occurrence, H, F, Cl, Br, I, CF_3, OCF_3, CN, NO_2, OR^a, $-CO_2R^a$, $-NR^7R^8$, $-SO_2R^c$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, or $-(CH_2)_r$-C_{3-10} carbocycle substituted with 0-3 R^d; ~~or $-(CH_2)_r$-5-10 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$, and substituted with 0-3 R^d;~~

R^{13} is H or C_1-C_4 alkyl;

each R^a is, independently at each occurrence, H, C_{1-4} alkyl, $-(CH_2)_r-CO_2R^g$, $-(CH_2)_r-C_{3-7}$ cycloalkyl, or $-(CH_2)_r-C_{6-10}$ aryl;

each R^f is, independently at each occurrence, H, =O, OR^g, F, Cl, Br, CF_3, CN, NO_2, $-NR^8R^9$, $-C(O)R^g$, $-C(O)OR^g$, $-NR^8C(O)R^g$, $-C(O)NR^8R^9$, $-SO_2NR^8R^9$, $-NR^8SO_2-C_{1-4}$ alkyl, $-NR^8SO_2CF_3$, $-S(O)_2CF_3$, $-S(O)_p-C_{1-4}$ alkyl, C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl;

each R^g is, independently at each occurrence, H or C_{1-4} alkyl;

p, at each occurrence, is selected from 0, 1, and 2; **and**

r, at each occurrence, is selected from 0, 1, 2, 3, and 4; ~~and~~

provided ring A is not substituted ortho to its attachment to the tetrahydroquinoline with OH, $-CO_2H$, $-C(O)O-C_{1-4}$ alkyl, O-phenyl, O-benzyl, $-NR^7R^8$, or $-NHSO_2C_{1-4}$ alkyl.

4. (Currently amended) A compound according to Claim 3, wherein:

A is phenyl substituted with 0-2 R^{11};

B is phenyl substituted with 0-2 R^{11} and 0-1 R^{12};

R^1 is -C(=NH)NH_2, -C(=O)NH_2, -CH_2NH_2, or OMe;

R^4 is phenyl substituted with 0-1 R^{4b};

R^{4b} is H, OH, or F;

R^5 is H, Me, Et, or Pr;

each R^{11} is, independently at each occurrence, H, F, OH, OMe, CN, -NH_2, -CH_2OH, -CO_2H, -CO_2Me, -NHCOMe, -NHCOEt, -NHCOPr, -NHCO(i-Pr), -NHCO(i-Bu), -NHCO(cyclopropyl), -NHCO(phenyl), -NHCO(2-CO_2H-phenyl), -NHCO(3-CO_2H-phenyl), -NHCO(4-CO_2H-phenyl), -NHCO(3,5-$(CO_2H)_2$-phenyl)-, -NHCO(3,5-$(CF_3)_2$-phenyl), -NHCO(3-Me-5-CO_2H-phenyl), -NHCO(3-(t-Bu)-5-CO_2H-phenyl), -NHCO(3-$CONH_2$-5-CO_2H-phenyl), -NHCO(3-NH_2-5-CO_2H-phenyl), -NHCO(benzyl), -NHCO(phenethyl), -NHCO(phenylpropyl), -NHCO[2-(2-pyridyl)-ethyl], -NHCO(tetrazol-5-yl), -NHCOCH_2(tetrazol-5-yl), -NHCO$(CH_2)_2$(tetrazol-5-yl), -$CONH_2$, -CONHMe, -CONH(i-Pr), -CONH(i-Bu), -CONH(t-Bu), -CONH(benzyl), -CONH(phenethyl), -CONH(phenylpropyl), -CONH[2-(2-pyridyl)-ethyl], -NHCONHMe, -NHCONHEt, -NHCH_2CO_2H, -NHCOCO_2H, -NHCOCH_2CO_2H, -NHCO$(CH_2)_2CO_2H$, -NHCO$(CH_2)_3CO_2H$, -$NHSO_2Me$, -$NHSO_2Et$, or -CH_2NMe_2;

R^{12} is -CO_2H, -$CH_2(CO_2H)$, -CO_2Me, -SO_2NH_2, or -$CONH_2$; **and**

R^{13} is H or Me; ~~and~~

provided ring A is not substituted ortho to its attachment to the tetrahydroquinoline with OH, -CO_2H, -CO_2Me, -NH_2, or -$NHSO_2C_{1-4}$ alkyl.

5. (Original) A compound according to Claim 4, wherein:

A is 1,2-phenylene, 4-OMe-1,2-phenylene, 3-CO_2H-1,2-phenylene, 4-OMe-5-OH-1,2-phenylene, 5-CH_2OH-1,2-phenylene, 5-NHCOMe-1,2-phenylene,

5-phenylcarbamoyl-1,2-phenylene, 5- benzylcarbamoyl-1,2-phenylene,
5-phenethylcarbamoyl-1,2-phenylene, 5-(3-phenylpropylcarbamoyl)-1,2-phenylene,
5-[2-(2-pyridyl)ethylcarbamoyl]-1,2-phenylene, 5-NHCO(i-Bu)-1,2-phenylene,
1,3-phenylene, 6-OMe-1,3-phenylene, 6-F-1,3-phenylene, 5-NH_2-1,3-phenylene,
5-NHCOMe-1,3-phenylene, 5-NHCOEt-1,3-phenylene, 5-NHCOPr-1,3-phenylene,
5-NHCO(i-Pr)-1,3-phenylene, 5-NHCO(i-Bu)-1,3-phenylene,
5-NHCO(cyclopropyl)-1,3-phenylene, 5-NHCONHEt-1,3-phenylene,
5-$NHCOCO_2H$-1,3-phenylene, 5-$NHCOCH_2CO_2H$-1,3-phenylene,
5-$NHCO(CH_2)_2CO_2H$-1,3-phenylene, 5-$NHCO(CH_2)_3CO_2H$-1,3-phenylene,
5-NHCO(phenyl)-1,3-phenylene, 5-NHCO(benzyl)-1,3-phenylene,
5-NHCO(2-CO_2H-phenyl)-1,3-phenylene, 5-NHCO(3-CO_2H-phenyl)-1,3-phenylene,
5-NHCO(4-CO_2H-phenyl)-1,3-phenylene,
5-NHCO(3,5-$(CO_2H)_2$-phenyl)-1,3-phenylene,
5-NHCO(3,5-$(CF_3)_2$-phenyl)-1,3-phenylene,
5-NHCO(3-Me-5-CO_2H-phenyl)-1,3-phenylene,
5-NHCO(3-(t-Bu)-5-CO_2H-phenyl)-1,3-phenylene,
5-NHCO(3-$CONH_2$-5-CO_2H-phenyl)-1,3-phenylene,
5-NHCO(3-NH_2-5-CO_2H-phenyl)-1,3-phenylene,
5-NHCO(tetrazol-5-yl)-1,3-phenylene, 5-$NHCOCH_2$(tetrazol-5-yl)-1,3-phenylene,
5-$NHCO(CH_2)_2$(tetrazol-5-yl)-1,3-phenylene, 5-$NHSO_2Et$-1,3-phenylene,
5-$NHCH_2CO_2H$-1,3-phenylene, or 3-CO_2H-1,4-phenylene;

B is 2-CO_2H-phenyl, 4-CO_2H-phenyl, 2-SO_2NH_2-phenyl,
3-$CH_2(CO_2H)$-phenyl, 2,4-$(CO_2H)_2$-phenyl, 2,4-$(CO_2Me)_2$-phenyl,
2,4-$(CONH_2)_2$-phenyl, 2-CO_2H-4-CO_2Me-phenyl, 2-CO_2H-4-NH_2-phenyl,
2-CO_2H-4-CN-phenyl, 2-CO_2H-4-OMe-phenyl, 2-CO_2H-4-NHAc-phenyl,
2-CO_2H-4-$CONH_2$-phenyl, 2-CO_2H-4-CONH(i-Pr)-phenyl,
2-CO_2H-4-C(O)NH(i-Bu)-phenyl, 2-CO_2H-4-C(O)NH(t-Bu)-phenyl,
2-CO_2H-4-NHCOMe-phenyl, 2-CO_2H-4-NHCONHMe-phenyl,

2-CO_2H-4-CH_2NMe_2-phenyl, or 2-CO_2H-4-$NHSO_2Me$-phenyl;

R^1 is -C(=NH)NH_2, -C(=O)NH_2, -CH_2NH_2, or OMe;

R^4 is phenyl, 4-OH-phenyl or 4-F-phenyl;

R^5 is H, Me, Et, or Pr; and

R^{13} is H or Me.

6. (Original) A compound of Claim 1 selected from:

2'-(6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-isobutylcarbamoyl-biphenyl-2-carboxylic acid;

2'-(6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-isobutylcarbamoyl-5'-hydroxy-4'-methoxy-biphenyl-2-carboxylic acid;

2'-[6-carbamimidoyl-4-(4-hydroxy-phenyl)-1,2,3,4-tetrahydro-quinolin-2-yl]-5'-hydroxy-4-isobutylcarbamoyl-4'-methoxy-biphenyl-2-carboxylic acid;

2'-(6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2,4-dicarboxylic acid dimethyl ester;

2'-(6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2,4-dicarboxylic acid;

2'-(6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2-carboxylic acid;

2'-(6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-4-carboxylic acid;

2'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2,4-dicarboxylic acid dimethyl ester;

2'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2,4-dicarboxylic acid;

3'-(6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-isobutylcarbamoyl-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-t-butylcarbamoyl-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2,4-dicarboxylic acid;

3'-(6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2-carboxylic acid;

4-phenyl-2-(2'-sulfamoyl-biphenyl-3-yl)-1,2,3,4-tetrahydro-quinoline-6-carboxamidine;

4-methyl-4-phenyl-2-(2'-sulfamoyl-biphenyl-3-yl)-1,2,3,4-tetrahydro-quinoline-6-carboxamidine;

3'-(6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2,4-dicarboxylic acid 4-methyl ester;

3'-(6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2,4-dicarboxylic acid diamide;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2,4-dicarboxylic acid;

3'-(6-carbamimidoyl-4-ethyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2,4-dicarboxylic acid;

3'-(6-carbamimidoyl-4-propylyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2,4-dicarboxylic acid;

4-amino-3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-(3-methyl-ureido)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-methanesulfonylamino-biphenyl-2-carboxylic acid;

4-acetylamino-3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-cyano-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2,4-dicarboxylic acid 4-methyl ester;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-methylcarbamoyl-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-isopropylcarbamoyl-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-t-butylcarbamoyl-biphenyl-2-carboxylic acid;

3'-[6-carbamimidoyl-4-(4-fluoro-phenyl)-4-methyl-1,2,3,4-tetrahydro-quinolin-2-yl]-4-carbamoyl-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-dimethylaminomethyl-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-3-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-biphenyl-2-carboxylic acid;

5'-amino-3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-biphenyl-2-carboxylic acid;

5'-amino-3'-(6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2-carboxylic acid;

5'-acetylamino-3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(3-methyl-butyrylamino)-biphenyl-2-carboxylic acid;

4-carbamoyl-3'-(6-carbamoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2-carboxylic acid;

4-carbamoyl-3'-(6-methoxy-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2-carboxylic acid;

3'-(6-aminomethyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(3-methyl-butyrylamino)-biphenyl-2-carboxylic acid;

3'-(6-aminomethyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(3-methyl-butyrylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(2-methylpropanoylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(n-propanoylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(cyclopropylcarbonylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-methoxyl-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(butyrylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-4'-methoxy-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-4'-fluoro-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(2-carboxyproacetylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(carboxycarbonylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(benzoylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(2-methylpropanoylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(2-phenylacetylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-(4-fluorophenyl)-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(2-methylpropanoylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(3-carboxypropanoylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(4-carboxybenzoylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(3-carboxybenzoylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(2-carboxybenzoylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(carboxymethylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(3,5-biscarboxybenzoylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-[(5-tetrazolyl)methylcarbonylamino]-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(4-carboxybutyrylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-[(5-tetrazoyl)carbonylamino]-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(3,5-bisfluorobenzoylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(3-amino-5-carboxybenzoylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-[2-(5-tetrazolyl)ethylcarbonylamino]-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(3-carboxy-5-methylbenzoylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(3-carboxy-5-t-butylbenzoylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(3-aminocarbonyl-5-carboxybenzoylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(ethylaminocarbonylamino)-biphenyl-2-carboxylic acid; and

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(ethylsulfonylamino)-biphenyl-2-carboxylic acid;

or a stereoisomer or a pharmaceutically acceptable salt or hydrate thereof.

7. (Original) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt or hydrate thereof.

8. (Original) A method for treating thromboembolic disorders, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt or hydrate thereof.

9. (Original) A method according to Claim 8, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart.

10. (Original) A method according to Claim 9, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.

11-23. (Canceled)

24. (Previously presented) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 2 or a pharmaceutically acceptable salt or hydrate thereof.

25. (Previously presented) A method for treating thromboembolic disorders, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 2 or a pharmaceutically acceptable salt or hydrate thereof.

26. (Previously presented) A method according to Claim 25, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart.

27. (Previously presented) A method according to Claim 26, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.

28. (Previously presented) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 3 or a pharmaceutically acceptable salt or hydrate thereof.

29. (Previously presented) A method for treating thromboembolic disorders, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 3 or a pharmaceutically acceptable salt or hydrate thereof.

30. (Previously presented) A method according to Claim 29, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart.

31. (Previously presented) A method according to Claim 30, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.

32. (Previously presented) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 4 or a pharmaceutically acceptable salt or hydrate thereof.

33. (Previously presented) A method for treating thromboembolic disorders, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 4 or a pharmaceutically acceptable salt or hydrate thereof.

34. (Previously presented) A method according to Claim 33, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart.

35. (Previously presented) A method according to Claim 34, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.

36. (Previously presented) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 5 or a pharmaceutically acceptable salt or hydrate thereof.

37. (Previously presented) A method for treating thromboembolic disorders, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 5 or a pharmaceutically acceptable salt or hydrate thereof.

38. (Previously presented) A method according to Claim 37, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart.

39. (Previously presented) A method according to Claim 38, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other

implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.

40. (Previously presented) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 6 or a pharmaceutically acceptable salt or hydrate thereof.

41. (Previously presented) A method for treating thromboembolic disorders, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 6 or a pharmaceutically acceptable salt or hydrate thereof.

42. (Previously presented) A method according to Claim 41, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart.

43. (Previously presented) A method according to Claim 42, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.